Incyte Corporation
INCY
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor tā¦ read more
Healthcare
Biotechnology
31 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$68.45
Price+0.41%
$0.28
1Y
Price
Market Cap
$13.250b
Large
Price/Earnings 3y Avg5y Avg
263.3x
Premium
Premium
Dividends
Ex-Dividend: -0.00%
Yield$0.00
Dividend0.00%
Forward Dividend Growth 3y CAGR5y CAGR
0.0%
Premium
Premium
Payout Payout 3yPayout 5y
0.0%
Premium
Premium
Yield
BenchmarkDividends
No items found.
Financials Overview
Key metrics over the past few years+24.4%
EBITDA Margin+15.0%
Net Profit Margin+25.0%
Free Cash Flow MarginRevenue
$4.413b
+4.1%
1y CAGR+9.2%
3y CAGR+10.3%
5y CAGREarnings
$21.270m
-34.8%
1y CAGR-18.0%
3y CAGR-29.5%
5y CAGREPS
$0.26
+73.3%
1y CAGR+17.8%
3y CAGR-2.8%
5y CAGRBook Value
$3.668b
$5.749b
Assets$2.082b
Liabilities$43.119m
DebtDebt to Assets
0.8%
0.1x
Debt to EBITDAFree Cash Flow
$288.810m
+16.0%
1y CAGR-26.1%
3y CAGR-5.3%
5y CAGRFinancial Reports
Earnings and other important metricsNo items found.
Press Releases
Statements and updates from the company